Infusion Pump Provides Flexibility for Sub-Q Ig Therapy

Vivaglobin^® and your patients’ lifestyles

While immunoglobulin (Ig) therapy is essential to maintaining your patients’ health, it’s a therapy that makes regular demands on their time—3.5 hours on average per infusion with the majority receiving infusions every 3 to 4 weeks.¹ That’s time taken away from work or school, family life, and social activities.

Ig therapy doesn’t have to slow patients down, interrupt their schedules, or interfere with their busy lives. What’s more, patients don’t have to be tied to an IV pole during their infusions.

With Vivaglobin^® and proper training, your patients can have control over their treatment schedule—for example, choosing to infuse weekly during a favorite prime time TV show rather than during an infusion clinic’s business hours. Because Vivaglobin^® uses a small portable pump, it allows patients to infuse their Ig in the comfort of their homes—or while traveling on business or vacation. In other words, self-administered Vivaglobin^® gives patients greater freedom and flexibility, allowing them to infuse their treatment when and where they want.

With Vivaglobin^®, your patients can maintain their Ig therapy compliance and their busy schedules.

Reference:

Treatment Experiences and Preferences of Patients With Primary Immune Deficiency: First National Survey. Immune Deficiency Foundation. June 20, 2003.

Next: Maintaining Steady-state lgG Levels

Important Safety Information

Immune Globulin Subcutaneous (Human), Vivaglobin^®, is indicated for the treatment of patients with primary immunodeficiency (PI).

As with all immune globulin products, Vivaglobin^® is contraindicated in individuals with a history of anaphylactic or severe systemic response to immune globulin preparations and in persons with selective immunoglobulin A deficiency who have known antibody against IgA. If anaphylactic or anaphylactoid reactions are suspected, discontinue administration immediately and treat as medically appropriate.

Vivaglobin^® is derived from human plasma. As with all plasma-derived products, the risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

In clinical trials, the most frequent adverse event was injection-site reaction, consisting of mild or moderate swelling, redness, and itching. No serious local site reactions were observed, and reactions tended to decrease substantially after repeated use. Other adverse events irrespective of causality included headache, gastrointestinal disorder, fever, nausea, sore throat, and rash.

As with all immune globulin (Ig) products, patients receiving Ig therapy for the first time, receiving a new product, or not having received Ig therapy within the preceding eight weeks may be at risk for developing reactions including fever, chills, nausea, and vomiting. On rare occasions, these reactions may lead to shock. Such patients should be monitored in a clinical setting during the initial administration.

Ig administration can transiently impair the efficacy of live attenuated virus vaccines, such as measles, mumps and rubella.

In clinical studies, administration of Vivaglobin^® has been shown to be safe and well tolerated in both adult and pediatric subjects. No pediatric-specific dose requirements were necessary to achieve the desired serum IgG levels. Safety and efficacy were not studied in pediatric subjects under two years of age.

Please see accompanying full prescribing information for Vivaglobin^®.

Please see Patient Product Information

Please see full Prescribing Information

Vivaglobin® and your patients’ lifestyles

Important Safety Information

Please see accompanying full prescribing information for Vivaglobin®.

Vivaglobin^® and your patients’ lifestyles

Please see accompanying full prescribing information for Vivaglobin^®.